Rehabkompassen® - a Patient-centered Digital Follow-up Tool in the Post-stroke Continuum of Care
Launched by UMEÅ UNIVERSITY · Jun 4, 2021
Trial Information
Current as of August 19, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial, called Rehabkompassen®, is looking at a new digital tool designed to help people who have had a stroke. The goal is to see if this tool can improve the way patients recover and manage their daily lives after being discharged from the hospital. By using the Rehabkompassen®, which collects information directly from patients about their health and experiences, researchers hope to create a more personalized rehabilitation plan that can lead to better overall health and quality of life.
To participate in this trial, individuals must be at least 18 years old and have had a stroke within the last four months. They should also have been discharged from a hospital. Participants will be divided into two groups: one will receive standard care, while the other will use the Rehabkompassen® tool along with their usual care. The study will track how effective the tool is in helping people regain their independence and improve their daily activities over a year. This is an exciting opportunity for stroke survivors to potentially benefit from a new approach to rehabilitation that is tailored to their specific needs.
Gender
ALL
Eligibility criteria
- • Inclusion criteria are
- • 1. Adults aged 18 years or older.
- • 2. With a stroke diagnosis
- Time since stroke onset:
- • 3a) For the big RCT group, Individuals must be within the first 4 months after stroke, starting from Day 1 after the occurrence of the stroke.
- • 3b) For primary care group, Individuals 3 months after stroke
- • Exclusion criteria are
- • 1. Unable to answer the evaluation questions.
- • 2. Unable to see the Rehabkompassen®graph.
- • 3. Not using BankID, an e-identification tool commonly used in Sweden.
About Umeå University
Umeå University, a leading research institution in Sweden, is dedicated to advancing healthcare through innovative clinical trials and translational research. With a strong emphasis on interdisciplinary collaboration, the university harnesses cutting-edge technology and expert knowledge across various fields to address critical health challenges. Its commitment to ethical standards and patient safety ensures that all clinical trials conducted under its auspices are designed to generate robust scientific evidence, ultimately contributing to improved health outcomes and informed medical practices. Umeå University strives to foster a dynamic research environment that supports the development of new therapies and enhances the understanding of complex health issues.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Umeå, , Sweden
Patients applied
Trial Officials
Xiaolei Hu, MD PhD
Principal Investigator
Umeå University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials